Table 1.

Demographic and clinical characteristics of patients at baseline

VariableAsciminib 40 mg twice daily
(n = 157)
Bosutinib 500 mg once daily
(n = 76)
All patients
(N = 233)
Median age (range), y 52.0 (24-83) 52.0 (19-77) 52.0 (19-83) 
Female, n (%) 75 (47.8) 45 (59.2) 120 (51.5) 
Male, n (%) 82 (52.2) 31 (40.8) 113 (48.5) 
Race, n (%)    
 White 118 (75.2) 56 (73.7) 174 (74.7) 
 Asian 22 (14.0) 11 (14.5) 33 (14.2) 
 Black or African American 8 (5.1) 2 (2.6) 10 (4.3) 
 Native American 1 (0.6) 1 (0.4) 
 Other 5 (3.2) 7 (9.2) 12 (5.2) 
 Unknown 3 (1.9) 3 (1.3) 
Ethnicity, n (%)    
 Hispanic or Latino 15 (9.6) 17 (22.4) 32 (13.7) 
 Not Hispanic or Latino 102 (65.0) 43 (56.6) 145 (62.2) 
 Not reported 23 (14.6) 11 (14.5) 34 (14.6) 
 Unknown 17 (10.8) 5 (6.6) 22 (9.4) 
ECOG performance status, n (%)    
 0 126 (80.3) 62 (81.6) 188 (80.7) 
 1 28 (17.8) 14 (18.4) 42 (18.0) 
 2 2 (1.3) 2 (0.9) 
 Missing 1 (0.6) 1 (0.4) 
MCyR 46 (29.3) 22 (28.9) 68 (29.2) 
Prior TKIs, n (%)    
 Imatinib 130 (82.8) 63 (82.9) 193 (82.8) 
 Nilotinib 104 (66.2) 56 (73.7) 160 (68.7) 
 Dasatinib 131 (83.4) 65 (85.5) 196 (84.1) 
 Ponatinib 23 (14.6) 18 (23.7) 41 (17.6) 
 Radotinib 4 (2.5) 2 (2.6) 6 (2.6) 
 Other 5 (3.2) 4 (5.3) 9 (3.9) 
No. of lines of prior TKI therapy, n (%)*    
 2 82 (52.2) 30 (39.5) 112 (48.1) 
 3 44 (28.0) 29 (38.2) 73 (31.3) 
 4 24 (15.3) 10 (13.2) 34 (14.6) 
 ≥5 7 (4.5) 7 (9.2) 14 (6.0) 
Reason for discontinuation of last TKI, n (%)    
 Lack of efficacy 95 (60.5) 54 (71.1) 149 (63.9) 
 Lack of tolerability 59 (37.6) 22 (28.9) 81 (34.8) 
 Other 3 (1.9) 3 (1.3) 
BCR-ABL1IS at baseline, n (%)    
 >0.1% to ≤1%§ 15 (9.6) 4 (5.3) NA 
 >1% to ≤10% 45 (28.7) 23 (30.3) NA 
 >10% 97 (61.8) 49 (64.5) NA 
Patients with any BCR-ABL1 mutation, n (%) 20 (12.7) 10 (13.2) 30 (12.9) 
Patients with multiple BCR-ABL1 mutations, n (%) 3 (1.9) 3 (1.3) 
VariableAsciminib 40 mg twice daily
(n = 157)
Bosutinib 500 mg once daily
(n = 76)
All patients
(N = 233)
Median age (range), y 52.0 (24-83) 52.0 (19-77) 52.0 (19-83) 
Female, n (%) 75 (47.8) 45 (59.2) 120 (51.5) 
Male, n (%) 82 (52.2) 31 (40.8) 113 (48.5) 
Race, n (%)    
 White 118 (75.2) 56 (73.7) 174 (74.7) 
 Asian 22 (14.0) 11 (14.5) 33 (14.2) 
 Black or African American 8 (5.1) 2 (2.6) 10 (4.3) 
 Native American 1 (0.6) 1 (0.4) 
 Other 5 (3.2) 7 (9.2) 12 (5.2) 
 Unknown 3 (1.9) 3 (1.3) 
Ethnicity, n (%)    
 Hispanic or Latino 15 (9.6) 17 (22.4) 32 (13.7) 
 Not Hispanic or Latino 102 (65.0) 43 (56.6) 145 (62.2) 
 Not reported 23 (14.6) 11 (14.5) 34 (14.6) 
 Unknown 17 (10.8) 5 (6.6) 22 (9.4) 
ECOG performance status, n (%)    
 0 126 (80.3) 62 (81.6) 188 (80.7) 
 1 28 (17.8) 14 (18.4) 42 (18.0) 
 2 2 (1.3) 2 (0.9) 
 Missing 1 (0.6) 1 (0.4) 
MCyR 46 (29.3) 22 (28.9) 68 (29.2) 
Prior TKIs, n (%)    
 Imatinib 130 (82.8) 63 (82.9) 193 (82.8) 
 Nilotinib 104 (66.2) 56 (73.7) 160 (68.7) 
 Dasatinib 131 (83.4) 65 (85.5) 196 (84.1) 
 Ponatinib 23 (14.6) 18 (23.7) 41 (17.6) 
 Radotinib 4 (2.5) 2 (2.6) 6 (2.6) 
 Other 5 (3.2) 4 (5.3) 9 (3.9) 
No. of lines of prior TKI therapy, n (%)*    
 2 82 (52.2) 30 (39.5) 112 (48.1) 
 3 44 (28.0) 29 (38.2) 73 (31.3) 
 4 24 (15.3) 10 (13.2) 34 (14.6) 
 ≥5 7 (4.5) 7 (9.2) 14 (6.0) 
Reason for discontinuation of last TKI, n (%)    
 Lack of efficacy 95 (60.5) 54 (71.1) 149 (63.9) 
 Lack of tolerability 59 (37.6) 22 (28.9) 81 (34.8) 
 Other 3 (1.9) 3 (1.3) 
BCR-ABL1IS at baseline, n (%)    
 >0.1% to ≤1%§ 15 (9.6) 4 (5.3) NA 
 >1% to ≤10% 45 (28.7) 23 (30.3) NA 
 >10% 97 (61.8) 49 (64.5) NA 
Patients with any BCR-ABL1 mutation, n (%) 20 (12.7) 10 (13.2) 30 (12.9) 
Patients with multiple BCR-ABL1 mutations, n (%) 3 (1.9) 3 (1.3) 

ECOG, Eastern Cooperative Oncology Group; NA, not available.

*

The number of lines of prior TKI therapy was based on the sequence of treatments.

Lack of efficacy criteria were based on 2013 ELN recommendations (see supplemental Appendix for details).

Includes study medication wrongly assigned, lack of efficacy and tolerability, and optimal response not reached after 5 y of treatment.

§

All patients with BCR-ABL1IS <1% at baseline were intolerant to the last TKI, except 1 in the asciminib arm (who deviated from the protocol).

or Create an Account

Close Modal
Close Modal